Harpoon Therapeutics, Inc.
PSMA targeting trispecific proteins and methods of use
Last updated:
Abstract:
Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
Status:
Grant
Type:
Utility
Filling date:
22 Nov 2017
Issue date:
24 Nov 2020